A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-CF113 in the treatment of endometriosis versus placebo after 3 medication cycles followed by 3 open-label medication cycles
Latest Information Update: 12 Jan 2024
At a glance
- Drugs Drospirenone (Primary)
- Indications Endometriosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Chemo Research, S.L.
- 12 Jan 2024 This study has been completed in Hungary, according to European Clinical Trials Database record.
- 20 Oct 2023 This trial has been completed in Slovakia (Global end date: 25 Sep 2023).
- 07 Oct 2023 This trial has been completed in Germany (Global end date: 25 Sep 2023).